Please note, this OEL/ADE monograph also applies to verapamil HCl (CAS RN 152-11-4). Verapamil is indicated for the treatment of multiple conditions including abnormal heartbeat, high blood pressure, rapid heartbeat and chestpain. Verapamil is an L-type calcium channel inhibitor (slow-channel blocker) that selectively blocks the transmembrane influx of calcium ions into arterial smooth muscles including conductile and contractile myocardial cells, without affecting the concentration of serum calcium. Its hypertensive effect is attributed to the reduction of systemic vascular resistance and selective vasodilation of peripheral arteries. Its antianginal effect is related to inhibition of coronary spasm, and relaxation of main coronary artery and coronary arterioles.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Verapamil, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.